QUARTERLY REPORT
Q1 2023 — Quarterly report
Q1 2023PDF · 59 pages818 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-16751
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value ELV New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”,
“smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No ☒
As of April 12, 2023, 237,055,805 shares of the Registrant’s Common Stock were outstanding.
-- 1 of 59 --
Elevance Health, Inc.
Quarterly Report on Form 10-Q
For the Period Ended March 31, 2023
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022 . . . . . . . . . . . . . 2
Consolidated Statements of Income (Unaudited) for the Three Months Ended March 31, 2023 and 2022 . 3
Consolidated Statements of Comprehensive Income (Unaudited) for the Three Months Ended March 31,
2023 and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2023 and
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Consolidated Statements of Changes in Equity (Unaudited) for the Three Months Ended March 31, 2023
and 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Notes to Consolidated Financial Statements (Unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK . . . . . . . . . . . . . . . 51
ITEM 4. CONTROLS AND PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
ITEM 1A. RISK FACTORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS . . . . . . . . . . . . . . . . 52
ITEM 3. DEFAULTS UPON SENIOR SECURITIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
ITEM 4. MINE SAFETY DISCLOSURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
ITEM 5. OTHER INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
ITEM 6. EXHIBITS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
-1-
-- 2 of 59 --
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Elevance Health, Inc.
Consolidated Balance Sheets
March 31,
2023 December 31,
2022
(In millions, except share and per share data) (Unaudited) (Restated)
Assets
Current assets:
Cash and cash equivalents $ 10,142 $ 7,387
Fixed maturity securities (amortized cost of $29,381 and $28,226; allowance for credit losses of $8 and $9) 27,636 25,952
Equity securities 392 953
Premium receivables 8,246 7,083
Self-funded receivables 3,786 4,663
Other receivables 4,678 4,298
Other current assets 4,943 5,281
Total current assets 59,823 55,617
Long-term investments:
Fixed maturity securities (amortized cost of $807 and $789; allowance for credit losses of $0 and $0) 783 752
Other invested assets 5,971 5,685
Property and equipment, net 4,418 4,316
Goodwill 25,273 24,383
Other intangible assets 10,915 10,315
Other noncurrent assets 1,857 1,687
Total assets $ 109,040 $ 102,755
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable $ 15,728 $ 15,596
Other policyholder liabilities 6,098 5,933
Unearned income 4,394 1,112
Accounts payable and accrued expenses 4,873 5,607
Short-term borrowings 265 265
Current portion of long-term debt — 1,500
Other current liabilities 10,531 9,683
Total current liabilities 41,889 39,696
Long-term debt, less current portion 25,201 22,349
Reserves for future policy benefits 811 803
Deferred tax liabilities, net 2,029 2,015
Other noncurrent liabilities 1,650 1,562
Total liabilities 71,580 66,425
Commitments and contingencies – Note 10
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none — —
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
237,114,190 and 237,958,067 2 2
Additional paid-in capital 8,697 9,084
Retained earnings 30,707 29,647
Accumulated other comprehensive loss (2,050) (2,490)
Total shareholders’ equity 37,356 36,243
Noncontrolling interests 104 87
Total equity 37,460 36,330
Total liabilities and equity $ 109,040 $ 102,755
See accompanying notes.
-2-
-- 3 of 59 --
Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited)
Three Months Ended
March 31
2023 2022
(In millions, except per share data) (Restated)
Revenues
Premiums $ 35,868 $ 32,785
Product revenue 4,022 3,301
Service fees 2,008 1,800
Total operating revenue 41,898 37,886
Net investment income 387 360
Net losses on financial instruments (113) (151)
Total revenues 42,172 38,095
Expenses
Benefit expense 30,786 28,231
Cost of products sold 3,481 2,883
Operating expense 4,800 4,345
Interest expense 251 201
Amortization of other intangible assets 235 129
Total expenses 39,553 35,789
Income before income tax expense 2,619 2,306
Income tax expense 615 527
Net income 2,004 1,779
Net (income) loss attributable to noncontrolling interests (15) 10
Shareholders’ net income $ 1,989 $ 1,789
Shareholders’ net income per share
Basic $ 8.37 $ 7.41
Diluted $ 8.30 $ 7.32
Dividends per share $ 1.48 $ 1.28
See accompanying notes.
-3-
-- 4 of 59 --
Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
March 31
(In millions) 2023 2022
(Restated)
Net income $ 2,004 $ 1,779
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments 427 (1,069)
Change in non-credit component of impairment losses on investments (2) (1)
Change in net unrealized gains/losses on cash flow hedges 11 3
Change in net periodic pension and postretirement costs 2 7
Change in future policy benefits 2 9
Foreign currency translation adjustments 2 (3)
Other comprehensive income (loss) 442 (1,054)
Net (income) loss attributable to noncontrolling interests (15) 10
Other comprehensive (income) loss attributable to noncontrolling interests (2) 5
Total shareholders’ comprehensive income $ 2,429 $ 740
See accompanying notes.
-4-
-- 5 of 59 --
Elevance Health, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended
March 31
2023 2022
(In millions) (Restated)
Operating activities
Net income $ 2,004 $ 1,779
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments 113 151
Equity in net earnings of other invested assets 30 (153)
Depreciation and amortization 462 358
Deferred income taxes (255) (96)
Share-based compensation 61 50
Changes in operating assets and liabilities:
Receivables, net (29) (1,348)
Other invested assets (15) 7
Other assets (348) (350)
Policy liabilities 306 1,092
Unearned income 3,282 57
Accounts payable and other liabilities 18 428
Income taxes 839 568
Other, net 1 (2)
Net cash provided by operating activities 6,469 2,541
Investing activities
Purchases of investments (7,443) (5,050)
Proceeds from sale of investments 2,489 3,047
Maturities, calls and redemptions from investments 3,533 1,209
Changes in securities lending collateral 204 (441)
Purchases of subsidiaries, net of cash acquired (1,638) (61)
Purchases of property and equipment (301) (254)
Other, net (28) (28)
Net cash used in investing activities (3,184) (1,578)
Financing activities
Net proceeds from commercial paper borrowings 325 225
Proceeds from long-term borrowings 2,574 —
Repayments of long-term borrowings (1,908) (14)
Changes in securities lending payable (205) 441
Changes in bank overdrafts (291) 529
Repurchase and retirement of common stock (622) (545)
Cash dividends (351) (309)
Proceeds from issuance of common stock under employee stock plans 43 76
Taxes paid through withholding of common stock under employee stock plans (98) (86)
Other, net 2 5
Net cash (used in) provided by financing activities (531) 322
Effect of foreign exchange rates on cash and cash equivalents 1 (4)
Change in cash and cash equivalents 2,755 1,281
Cash and cash equivalents at beginning of period 7,387 4,880
Cash and cash equivalents at end of period $ 10,142 $ 6,161
See accompanying notes.
-5-
-- 6 of 59 --
Elevance Health, Inc.
Consolidated Statements of Changes in Equity
(Unaudited)
Total Shareholders’ Equity
Common Stock Additional
Paid-in
Capital Retained
Earnings
Accumulated
Other
Comprehensive
Loss Noncontrolling
Interests Total
Equity (In millions) Number of
Shares Par
Value
December 31, 2022 (restated) 238.0 $ 2 $ 9,084 $ 29,647 $ (2,490) $ 87 $ 36,330
Net income — — — 1,989 — 15 2,004
Other comprehensive income — — — — 440 2 442
Repurchase and retirement of
common stock, including excise
tax (1.3) — (51) (575) — — (626)
Dividends and dividend
equivalents — — — (354) — — (354)
Issuance of common stock under
employee stock plans, net of
related tax benefits 0.4 — 6 — — — 6
Convertible debenture repurchases,
conversions and tax adjustments — — (342) — — — (342)
March 31, 2023 237.1 $ 2 $ 8,697 $ 30,707 $ (2,050) $ 104 $ 37,460
December 31, 2021 (restated) 241.8 $ 2 $ 9,148 $ 27,142 $ (197) $ 68 $ 36,163
Adoption of Accounting Standards
Update 2020-06 — — — (23) — — (23)
January 1, 2022 241.8 2 9,148 27,119 (197) 68 36,140
Net income (loss) (restated) — — — 1,789 — (10) 1,779
Other comprehensive loss
(restated) — — — — (1,049) (5) (1,054)
Noncontrolling interests adjustment — — — — — 3 3
Repurchase and retirement of
common stock (1.2) — (45) (500) — — (545)
Dividends and dividend
equivalents — — — (312) — — (312)
Issuance of common stock under
employee stock plans, net of
related tax benefits 0.5 — 39 — — — 39
Convertible debenture repurchases
and conversions — — 9 — — — 9
March 31, 2022 (restated) 241.1 $ 2 $ 9,151 $ 28,096 $ (1,246) $ 56 $ 36,059
See accompanying notes.
-6-
-- 7 of 59 --
Elevance Health, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
March 31, 2023
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial
Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and
indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise
requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving greater than 48 million medical members
through our affiliated health plans as of March 31, 2023. We offer a broad spectrum of network-based managed care risk-
based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of
managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access,
medical management, care management, wellness programs, actuarial services and other administrative services. We provide
services to the federal government in connection with our Federal Health Products & Services business, which administers
the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of
our subsidiary health plans and also unaffiliated health plans, including pharmacy services and dental, vision, life, disability
and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and
Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (with the exception
of 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a
majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue
Cross Blue Shield or Empire Blue Cross. We also serve members in numerous states as Amerigroup, Freedom Health,
HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, UniCare and/or Wellpoint. We also conduct
business through arrangements with other BCBS licensees as well as other strategic partners. We are licensed to conduct
insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various
subsidiaries, we also offer pharmacy services as CarelonRx and other healthcare-related services as Carelon Services, Aspire
Health, Carelon Behavioral Health and CareMore.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-
to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans; and
• Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and
Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023.
The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our
previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services
(previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the
quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
-7-
-- 8 of 59 --
segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial
& Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has
been reclassified to conform to the new presentation. For additional discussion regarding our segments, including the changes
made, see Note 14 “Segment Information.”
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance
with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not
include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain
footnote disclosures that would substantially duplicate the disclosures in our 2022 Annual Report on Form 10-K, unless the
information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all
adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements
as of and for the three months ended March 31, 2023 and 2022 have been recorded. The results of operations for the three
months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year ending
December 31, 2023, or any other period. The seasonal nature of portions of our health care and related benefits business, as
well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim
results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited
consolidated financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on
Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar
(“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during
the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our
consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for
the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory
requirements. These amounts totaled $520 and $258 at March 31, 2023 and December 31, 2022, respectively, and are
included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those
securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we
classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy
contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it
is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we
write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements
of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not
have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment
loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated
other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed
maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated
other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future
cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our
best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of
purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the
underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default
rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
-8-
-- 9 of 59 --
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated
with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on
anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the
effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date
of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains
and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are
reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other
members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the
caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to
influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of
these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under
the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on
the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities
sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred
to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which
is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding
liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current
liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate
component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in
non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value
of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities
and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily,
the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises.
The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality
and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is
based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government
programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $149 and
$152 at March 31, 2023 and December 31, 2022, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for
administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $76 and $68 at
March 31, 2023 and December 31, 2022, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due
from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables
are reported net of an allowance for doubtful accounts of $763 and $744 at March 31, 2023 and December 31, 2022,
respectively.
-9-
-- 10 of 59 --
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or
deferred contract costs recorded on our consolidated balance sheet at March 31, 2023. For the three months ended March 31,
2023 and 2022, revenue recognized from performance obligations related to prior periods, such as changes in transaction
price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to
be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable
consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”)
issued Accounting Standards Update No.2020-11. Financial Services—Insurance (Topic 944): Effective Date and Early
Application (“ASU 2020-11”). The amendments in ASU 2020-11 change the effective date and early application of
Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the
Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU
2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual
reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our
long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net
income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in
these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be
based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that
of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these
amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future
policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an
overall material impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the
impacts of our adoption as required by the new standard.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our
2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position,
results of operations or cash flows.
3. Business Acquisitions and Divestitures
Pending Divestiture
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp
Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and
individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected
to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals. The
related net assets held for sale and results of operations for the employee benefits businesses to be divested as of and for the
period ending March 31, 2023 were not material.
Pending Acquisition
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity
Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides
healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana.
This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health
solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject
to standard closing conditions and customary approvals.
Completed Acquisitions
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from
CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy
organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of
specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition
aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs
that improve the lives of the people we serve. As of March 31, 2023, the purchase price was allocated to the tangible and
-10-
-- 11 of 59 --
intangible net assets acquired based on management’s initial estimates of their fair values, of which $809 has been allocated
to finite-lived intangible assets and $728 to goodwill. The majority of goodwill is not deductible for income tax purposes. As
of March 31, 2023, the initial accounting for the acquisition had not been finalized. The proforma effects of this acquisition
for prior periods were not material to our consolidated results of operations.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term
care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live
safely and independently in their own homes. The purchase price was allocated to tangible and intangible net assets acquired
based on management's estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250
to indefinite-lived intangible assets, and $125 to goodwill. The majority of goodwill is deductible for income tax purposes.
There were no measurement period adjustments during the quarter ended March 31, 2023, and as of March 31, 2023, the
initial accounting for the acquisition had not been finalized. The proforma effects of this acquisition for prior periods were
not material to our consolidated results of operations.
4. Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We
have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment
losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty
of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value
may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
-11-
-- 12 of 59 --
A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2023 and December 31,
2022 is as follows:
Cost or
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Allowance
For Credit
Losses Estimated
Fair Value
March 31, 2023
Fixed maturity securities:
United States Government securities $ 2,053 $ 8 $ (66) $ — $ 1,995
Government sponsored securities 80 1 (3) — 78
Foreign government securities 332 2 (43) (1) 290
States, municipalities and political subdivisions, tax-exempt 4,339 38 (192) — 4,185
Corporate securities 13,834 78 (956) (5) 12,951
Residential mortgage-backed securities 3,165 15 (281) — 2,899
Commercial mortgage-backed securities 2,243 2 (173) (2) 2,070
Other asset-backed securities 4,142 17 (208) — 3,951
Total fixed maturity securities $ 30,188 $ 161 $ (1,922) $ (8) $ 28,419
December 31, 2022
Fixed maturity securities:
United States Government securities $ 1,502 $ 2 $ (103) $ — $ 1,401
Government sponsored securities 82 1 (5) — 78
Foreign government securities 321 1 (46) (2) 274
States, municipalities and political subdivisions, tax-exempt 4,389 19 (265) — 4,143
Corporate securities 13,721 31 (1,218) (5) 12,529
Residential mortgage-backed securities 2,978 9 (324) — 2,663
Commercial mortgage-backed securities 2,055 1 (176) (2) 1,878
Other asset-backed securities 3,967 12 (241) — 3,738
Total fixed maturity securities $ 29,015 $ 76 $ (2,378) $ (9) $ 26,704
Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.
-12-
-- 13 of 59 --
For fixed maturity securities in an unrealized loss position at March 31, 2023 and December 31, 2022, the following
table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously
been in an unrealized loss position:
Less than 12 Months 12 Months or Greater
(Securities are whole amounts) Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss
March 31, 2023
Fixed maturity securities:
United States Government securities 39 $ 490 $ (13) 47 $ 393 $ (53)
Government sponsored securities 15 38 (1) 30 19 (2)
Foreign government securities 80 40 (3) 231 186 (40)
States, municipalities and political
subdivisions, tax-exempt 468 945 (12) 967 1,689 (180)
Corporate securities 1,878 3,636 (114) 3,207 6,687 (842)
Residential mortgage-backed securities 532 579 (25) 1,224 1,730 (256)
Commercial mortgage-backed securities 260 679 (24) 558 1,298 (149)
Other asset-backed securities 364 1,067 (59) 775 2,149 (149)
Total fixed maturity securities 3,636 $ 7,474 $ (251) 7,039 $ 14,151 $ (1,671)
December 31, 2022
Fixed maturity securities:
United States Government securities 61 $ 701 $ (40) 38 $ 442 $ (63)
Government sponsored securities 39 73 (4) 6 5 (1)
Foreign government securities 150 100 (10) 198 142 (36)
States, municipalities and political
subdivisions, tax-exempt 1,398 2,615 (147) 396 652 (118)
Corporate securities 3,551 7,826 (549) 2,204 3,521 (669)
Residential mortgage-backed securities 1,341 1,435 (121) 496 982 (203)
Commercial mortgage-backed securities 457 1,082 (76) 324 719 (100)
Other asset-backed securities 784 2,203 (124) 398 1,074 (117)
Total fixed maturity securities 7,781 $ 16,035 $ (1,071) 4,060 $ 7,537 $ (1,307)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of March
31, 2023, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior
to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the
higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amounts of $8 and $9 at March 31, 2023 and December 31, 2022,
respectively, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our
assessment of collectability of principal and interest.
-13-
-- 14 of 59 --
The amortized cost and fair value of fixed maturity securities at March 31, 2023, by contractual maturity, are shown
below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to
prepay obligations.
Amortized
Cost Estimated
Fair Value
Due in one year or less $ 1,242 $ 1,232
Due after one year through five years 7,892 7,557
Due after five years through ten years 9,334 8,806
Due after ten years 6,312 5,855
Mortgage-backed securities 5,408 4,969
Total fixed maturity securities $ 30,188 $ 28,419
During the three months ended March 31, 2023 and 2022, we received total proceeds from sales, maturities, calls or
redemptions of fixed maturity securities of $5,410 and $3,646, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to:
(i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce
exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are
determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at March 31, 2023 and December 31, 2022 is as follows:
March 31, 2023 December 31, 2022
Equity securities:
Exchange traded funds $ 288 $ 822
Common equity securities 26 43
Private equity securities 78 88
Total $ 392 $ 953
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled
corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited
partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed
earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three
month lag due to the timing of when we receive financial information from the companies.
-14-
-- 15 of 59 --
Investment Gains and Losses
Net investment (losses) gains for the three months ended March 31, 2023 and 2022 are as follows:
Three Months Ended March 31
2023 2022
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales $ 10 $ 20
Gross realized losses from sales (115) (78)
Impairment losses recognized in income (7) (20)
Net realized losses from sales of fixed maturity securities (112) (78)
Equity securities:
Unrealized losses recognized on equity securities still held at the end of the
period (1) (71)
Net realized losses recognized on equity securities sold during the period (1) (14)
Net losses on equity securities (2) (85)
Other investments:
Gross gains 27 23
Gross losses (1) (30)
Impairment losses recognized in income (3) (4)
Net gains (losses) on other investments 23 (11)
Net losses on investments $ (91) $ (174)
Accrued Investment Income
At March 31, 2023 and December 31, 2022, accrued investment income totaled $256 and $245, respectively. We
recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred
to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the
time of the transactions amounted to $2,252 and $2,457 at March 31, 2023 and December 31, 2022, respectively. The value
of the collateral represented 102% of the market value of the securities on loan at each of March 31, 2023 and December 31,
2022. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and
we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other
current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance
sheets.
At March 31, 2023 and December 31, 2022, the remaining contractual maturity of our securities lending agreements
included overnight and continuous transactions of cash for $2,127 and $2,221, respectively, of United States Government
securities for $104 and $224, respectively, and of Residential Mortgage-Backed securities for $21 and $12, respectively.
5. Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward
contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements,
which reduce credit risk by permitting net settlement of transactions.
-15-
-- 16 of 59 --
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-
term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to
LIBOR or the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these
derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other
noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive
loss, net of tax, was $217 and $229 at March 31, 2023 and December 31, 2022, respectively.
During the three months ended March 31, 2023, we recognized net losses on non-hedging derivatives of $22. During the
three months ended March 31, 2022, we recognized net gains on non-hedging derivatives of $23.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of
this Form 10-Q.
6. Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of
judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair
value measurements and disclosures, are as follows:
Level Input Input Definition
Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through
corroboration with market data at the measurement date.
Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing
the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following
assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three
months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of
the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on
quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which
generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and
disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain
other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of
comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets
for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to
determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and
pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies
include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also
have certain fixed maturity securities, primarily collateralized loan obligation securities and corporate debt securities, that are
designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted
cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates
and prepayment speeds that are not observable in the markets.
-16-
-- 17 of 59 --
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market
prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value
is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II.
We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each
security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these
private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions
for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes,
depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where
available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II
inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the
derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate
observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives
presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by
counterparty.
-17-
-- 18 of 59 --
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at
March 31, 2023 and December 31, 2022 is as follows:
Level I Level II Level III Total
March 31, 2023
Assets:
Cash equivalents $ 6,277 $ — $ — $ 6,277
Fixed maturity securities, available-for-sale:
United States Government securities — 1,995 — 1,995
Government sponsored securities — 78 — 78
Foreign government securities — 290 — 290
States, municipalities and political subdivisions, tax-exempt — 4,185 — 4,185
Corporate securities — 12,809 142 12,951
Residential mortgage-backed securities — 2,899 — 2,899
Commercial mortgage-backed securities — 2,070 — 2,070
Other asset-backed securities — 3,561 390 3,951
Total fixed maturity securities, available-for-sale — 27,887 532 28,419
Equity securities:
Exchange traded funds 288 — — 288
Common equity securities 13 13 — 26
Private equity securities — — 78 78
Total equity securities 301 13 78 392
Other invested assets - common equity securities 127 — — 127
Securities lending collateral — 2,252 — 2,252
Derivatives - other assets — 9 — 9
Total assets $ 6,705 $ 30,161 $ 610 $ 37,476
Liabilities:
Derivatives - other liabilities $ — $ (50) $ — $ (50)
Total liabilities $ — $ (50) $ — $ (50)
December 31, 2022
Assets:
Cash equivalents $ 3,567 $ — $ — $ 3,567
Fixed maturity securities, available-for-sale:
United States Government securities — 1,401 — 1,401
Government sponsored securities — 78 — 78
Foreign government securities — 274 — 274
States, municipalities and political subdivisions, tax-exempt — 4,143 — 4,143
Corporate securities — 12,392 137 12,529
Residential mortgage-backed securities — 2,663 — 2,663
Commercial mortgage-backed securities — 1,878 — 1,878
Other asset-backed securities — 3,382 356 3,738
Total fixed maturity securities, available-for-sale — 26,211 493 26,704
Equity securities:
Exchange traded funds 822 — — 822
Common equity securities 2 41 — 43
Private equity securities — — 88 88
Total equity securities 824 41 88 953
Other invested assets - common equity securities 103 — — 103
Securities lending collateral — 2,457 — 2,457
Derivatives - other assets — 3 — 3
Total assets $ 4,494 $ 28,712 $ 581 $ 33,787
Liabilities:
Derivatives - other liabilities $ — $ (60) $ — $ (60)
Total liabilities $ — $ (60) $ — $ (60)
-18-
-- 19 of 59 --
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level
III inputs for the three months ended March 31, 2023 and 2022 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other Asset-
backed
Securities Equity
Securities Total
Three Months Ended March 31, 2023
Beginning balance at January 1, 2023 $ 137 $ — $ 356 $ 88 $ 581
Total losses:
Recognized in net income — — (1) (6) (7)
Purchases 17 — 41 — 58
Sales (9) — (6) (4) (19)
Settlements (2) — — — (2)
Transfers out of Level III (1) — — — (1)
Ending balance at March 31, 2023 $ 142 $ — $ 390 $ 78 $ 610
Change in unrealized losses included in net income related to
assets still held at March 31, 2023 $ — $ — $ — $ (7) $ (7)
Three Months Ended March 31, 2022
Beginning balance at January 1, 2022 $ 336 $ 5 $ 19 $ 89 $ 449
Total gains (losses):
Recognized in net income 1 — — 3 4
Recognized in accumulated other comprehensive loss (2) (1) 1 — (2)
Purchases 46 — 17 8 71
Sales (7) — — (1) (8)
Settlements (33) — — — (33)
Ending balance at March 31, 2022 $ 341 $ 4 $ 37 $ 99 $ 481
Change in unrealized gains included in net income related to
assets still held at March 31, 2022 $ — $ — $ — $ 3 $ 3
There were no individually material transfers into or out of Level III during the three months ended March 31, 2023 or
2022.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured
at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in
Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of BioPlus in February 2023 and Integra in
May 2022. The net assets acquired in our acquisitions of BioPlus and Integra and resulting goodwill and other intangible
assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities
assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair
values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of
BioPlus and Integra were internally estimated based on the income approach. The income approach estimates fair value based
on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal
estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and
liabilities assumed in our acquisitions of BioPlus and Integra described above, there were no material assets or liabilities
measured at fair value on a nonrecurring basis during the three months ended March 31, 2023 or 2022.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our
policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes.
Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow
analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for
the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could
have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value
measurements, if significant, may affect performance of cash flows.
-19-
-- 20 of 59 --
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally
to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades
for identical or similar securities making adjustments through the reporting date based upon available market observable
information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the
pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our
internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation
techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price
comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing
services during the three months ended March 31, 2023 or 2022.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB
guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to
estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes,
intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures.
Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables,
other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate
fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is
recorded at its carrying value in our consolidated balance sheets:
Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and
other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance
policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in
the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which
approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as
reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or
similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us
for debt of similar terms and remaining maturities.
Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the
underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market
prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market
observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market
price in the active private market in which the convertible debentures trade.
-20-
-- 21 of 59 --
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value
on our consolidated balance sheets at March 31, 2023 and December 31, 2022 is as follows:
Carrying
Value
Estimated Fair Value
Level I Level II Level III Total
March 31, 2023
Assets:
Other invested assets $ 5,844 $ — $ — $ 5,844 $ 5,844
Liabilities:
Debt:
Short-term borrowings 265 — 265 — 265
Commercial paper 325 — 325 — 325
Notes 24,876 — 23,371 — 23,371
December 31, 2022
Assets:
Other invested assets $ 5,582 $ — $ — $ 5,582 $ 5,582
Liabilities:
Debt:
Short-term borrowings 265 — 265 — 265
Notes 23,786 — 21,861 — 21,861
Convertible debentures 63 — 463 — 463
7. Income Taxes
During the three months ended March 31, 2023 and 2022, we recognized income tax expense of $615 and $527
(restated), respectively, which represent effective income tax rates of 23.5% and 22.9% (restated), respectively. The increase
in the income tax rate in 2023 primarily relates to the tax impact of expected geographic changes in our mix of 2023 earnings
and reduced investment tax credits.
Income taxes payable totaled $399 at March 31, 2023 and income tax receivable was $440 at December 31, 2022. We
recognize the income tax payable as a liability under the caption “Other current liabilities” and the income receivable as an
asset under the caption “Other current assets” in our consolidated balance sheets.
-21-
-- 22 of 59 --
8. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, for the three months ended March 31,
2023 and 2022 is as follows:
2023 2022
Gross medical claims payable, beginning of period $ 15,348 $ 13,282
Ceded medical claims payable, beginning of period (6) (21)
Net medical claims payable, beginning of period 15,342 13,261
Business combinations and purchase adjustments — 3
Net incurred medical claims:
Current period 30,751 28,064
Prior periods redundancies (1,068) (933)
Total net incurred medical claims 29,683 27,131
Net payments attributable to:
Current period medical claims 19,948 17,116
Prior periods medical claims 9,593 8,826
Total net payments 29,541 25,942
Net medical claims payable, end of period 15,484 14,453
Ceded medical claims payable, end of period 7 17
Gross medical claims payable, end of period $ 15,491 $ 14,470
At March 31, 2023, the total of net incurred but not reported liabilities plus expected development on reported claims
was $644, $4,036 and $10,804 for the claim years 2021 and prior, 2022 and 2023, respectively.
The favorable development recognized in the three months ended March 31, 2023 and 2022 resulted primarily from
trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable
development in the completion factors resulting from the latter parts of 2022 developing faster than expected also contributed
to the favorable development in the three months ended March 31, 2023.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income
for the three months ended March 31, 2023 and 2022 is as follows:
2023 2022
(Restated)
Total net incurred medical claims $ 29,683 $ 27,131
Quality improvement and other claims expense 1,103 1,100
Benefit expense $ 30,786 $ 28,231
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for
medical claims payable included in the consolidated balance sheet, as of March 31, 2023, is as follows:
Total
Net medical claims payable, end of period $ 15,484
Ceded medical claims payable, end of period 7
Insurance lines other than short duration 237
Gross medical claims payable, end of period $ 15,728
-22-
-- 23 of 59 --
9. Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At March 31, 2023 and December 31,
2022, we had $24,851 and $23,761, respectively, outstanding under these notes.
On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000
aggregate principal amount of 4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125%
Notes due 2053 (the “2053 Notes”) under our shelf registration statement. Interest on the 2026 Notes is payable semi-
annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the 2033 Notes and
2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023.
We intend to use the proceeds for working capital and general corporate purposes, including, but not limited to, the funding
of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share
repurchase program.
On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On
March 15, 2023, we repaid, at maturity, the $500 outstanding balance of our 0.450% senior unsecured notes.
We have an unsecured surplus note with an outstanding principal balance of $25 at both March 31, 2023 and
December 31, 2022.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year
Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-
capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year
Facility. As of March 31, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 40.5%. We
do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating
flexibility. As of March 31, 2023, we were in compliance with all of our debt covenants under the 5-Year Facility. There
were no amounts outstanding under the 5-Year Facility at any time during the three months ended March 31, 2023 or the year
ended December 31, 2022.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”)
with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200.
Our ability to borrow under the Subsidiary Credit Facilities is subject to compliance with certain covenants. At March 31,
2023 and December 31, 2022, we had no outstanding borrowings under the Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general
corporate purposes. At March 31, 2023 and December 31, 2022, we had $325 and $0, respectively, outstanding under this
program.
On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the
“Debentures”), pursuant to the indenture dated as of October 9, 2012 between us and The Bank of New York Mellon Trust
Company, N.A., as trustee. The Debentures were redeemed at a redemption price equal to 100% of the principal amount of
the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption, for cash totaling $5. During the
three months ended March 31, 2023, $59 aggregate principal amount of the Debentures was surrendered for conversion by
certain holders in accordance with the terms and conditions of the indenture. We elected to settle the excess of the principal
amount of the conversions with cash for total payments during the three months ended March 31, 2023 of $404.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively,
the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. We had $265 of outstanding short-term borrowings from the FHLBs at each of March 31, 2023 and
December 31, 2022.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLBs borrowings and the
Subsidiary Credit Facilities.
-23-
-- 24 of 59 --
10. Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or
proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court
filings, the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to
the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious
defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated
financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to
income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In
addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a
previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or
range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses,
or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to
some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages,
(iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the
class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be
resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For
those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate
the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of
established reserves is, in the aggregate, from $0 to approximately $250 at March 31, 2023. This estimated aggregate range
of reasonably possible losses is based upon currently available information taking into account our best estimate of such
losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue
Shield licensees (the “Blue plans”) across the country. Cases filed in 28 states were consolidated into a single, multi-district
proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the
Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to
horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue
revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other
arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by
two putative nationwide classes of plaintiffs, health plan subscribers and providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the
defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of
review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of
reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of
the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of
genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber
Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement
Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-
monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule
limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers
with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue
plan.
-24-
-- 25 of 59 --
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following
which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to
opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval
Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be
available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, the
Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the
Company of $596, which amount was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those
appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event that all appellate rights are
exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations
under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in
accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for
class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for
class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that
order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment
motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain
defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against
such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v.
American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting
in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the
elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation
conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review,
reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. In November 2022, the
Court issued an order requiring the parties to submit supplemental briefs on certain questions related to providers’ renewed
motion for class certification. We intend to continue to vigorously defend the provider litigation, which we believe is without
merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed.
Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) ("Alaska Air");
JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) ("Jet Blue"); Metropolitan
Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath &
Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.) ("Bed Bath & Beyond"); Hoover, et al. v. Blue Cross Blue
Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al.,
No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendants’ motion to dismiss on statute of
limitations in Alaska Air and Jet Blue. In March 2023, pursuant to a stipulation by the parties, the Court denied the
defendants’ motion to dismiss on the statute of limitations in Bed Bath & Beyond. We intend to continue to vigorously defend
these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was
named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”)
captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that
permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce
governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation
despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required
to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC
has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends
that BCC must pay the GPT rather than the CFT and seeks a writ of mandate directing the taxing agencies to collect the GPT
-25-
-- 26 of 59 --
and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the
complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims
with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its
rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax
periods at issue in the litigation.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by
other entities. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s
lawsuit. In November 2021, the plaintiff appealed the summary judgment order. BCC’s responding brief was filed in March
2022 and Plaintiff’s reply was filed in May 2022. In March 2023, the appeal was argued before the California Second District
Court of Appeal. We expect a ruling in April 2023. We intend to continue to vigorously defend this suit, which we believe is
without merit; however, the ultimate outcome cannot be presently determined.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for pharmacy
benefit management services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern
District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that
is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in
damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express
Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to
provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement;
and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one
year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the
periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level
of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is
to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly
enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted
our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing,
and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of
contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In
March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The
District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most
of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of
this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization
processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express
Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims,
which we opposed, and the District Court denied in March 2023, allowing our operational breach claim to proceed. A trial
date has been set for December 2023. We intend to appeal the earlier summary judgment decision at the appropriate time,
vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate
outcome of this litigation cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S.
District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v.
Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we
submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C
and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts,
we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to
obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended
-26-
-- 27 of 59 --
complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we
filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to
strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In
November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was
held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert
discovery to be complete by February 2025. We intend to continue to vigorously defend this suit, which we believe is without
merit; however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data
submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of
our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore
investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our
HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December
2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to
CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal
and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the
Civil Division of the DOJ related to its investigation. We have submitted corrected data to CMS related to these
investigations. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for,
among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our
investigation. While certain elements of the indemnity claims were resolved in the fourth quarters of 2021 and 2022,
litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve
claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”)
and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred
Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees
arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results
in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability
under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage
claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the
character incidental to our business and are from time to time involved as a party in various governmental investigations,
audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include
routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and
subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the
imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our
business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material
adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related
management and support services through June 2025. The agreement superseded certain prior agreements for such services
and includes provisions for additional services not provided under those agreements. Our remaining commitment under this
agreement at March 31, 2023 is approximately $697. We will have the ability to terminate the agreement upon the occurrence
of certain events, subject to early termination fees.
We formed CarelonRx, formerly known as IngenioRx, to market and offer pharmacy services to our affiliated health plan
customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The
comprehensive pharmacy services portfolio includes, but is not limited to, formulary management, pharmacy networks,
specialty and home delivery pharmacy services and member services. CarelonRx delegates certain pharmacy services, such
-27-
-- 28 of 59 --
as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health
Corporation, pursuant to a five-year agreement, which is set to terminate on December 31, 2024. With CarelonRx, we retain
the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales,
marketing, account management and retail network strategy.
11. Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the three months ended March 31, 2023 and 2022 is as follows:
Declaration Date Record Date Payment Date
Cash
Dividend
per Share Total
Three Months Ended March 31, 2023
January 24, 2023 March 10, 2023 March 24, 2023 $1.48 $ 351
Three Months Ended March 31, 2022
January 25, 2022 March 10, 2022 March 25, 2022 $1.28 $ 309
On April 18, 2023, our Audit Committee declared a second quarter 2023 dividend to shareholders of $1.48 per share,
payable on June 23, 2023 to shareholders of record at the close of business on June 9, 2023.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023,
our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the
common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve
the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices,
subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open
market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to
comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is
discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe
it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to
additional paid-in capital and retained earnings.
A summary of common stock repurchases for the three months ended March 31, 2023 and 2022 is as follows:
Three Months Ended March 31
2023 2022
Shares repurchased 1.3 1.2
Average price per share $ 476.66 $ 453.32
Aggregate cost $ 622 $ 545
Authorization remaining at the end of the period $ 6,254 $ 3,647
For additional information regarding the use of capital for debt security repurchases, see Note 9, “Debt,” included in this
Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31,
2022 included in our 2022 Annual Report on Form 10-K.
-28-
-- 29 of 59 --
Stock Incentive Plans
A summary of stock option activity for the three months ended March 31, 2023 is as follows:
Number of
Shares
Weighted-
Average
Option Price
per Share
Weighted-
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2023 2.8 $ 293.28
Granted 0.6 469.03
Exercised (0.1) 271.70
Forfeited or expired — 366.61
Outstanding at March 31, 2023 3.3 322.65 6.72 $ 458
Exercisable at March 31, 2023 2.2 265.17 5.52 $ 424
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for
the three months ended March 31, 2023 is as follows:
Restricted
Stock Shares
and Units
Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2023 1.2 $ 357.21
Granted 0.6 469.31
Vested (0.6) 300.41
Forfeited — 387.32
Nonvested at March 31, 2023 1.2 420.84
During the three months ended March 31, 2023, we granted approximately 0.2 restricted stock units that are contingent
upon us achieving earnings targets over the three-year period from 2023 to 2025. These grants have been included in the
activity shown above but will be subject to adjustment at the end of 2025 based on results in the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed
discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated
financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the three
months ended March 31, 2023 and 2022:
Three Months Ended March 31
2023 2022
Risk-free interest rate 3.95 % 1.97 %
Volatility factor 29.00 % 29.00 %
Quarterly dividend yield 0.316 % 0.282 %
Weighted-average expected life (years) 4.40 5.10
-29-
-- 30 of 59 --
The following weighted-average fair values per option or share were determined for the three months ended March 31,
2023 and 2022:
Three Months Ended March 31
2023 2022
Options granted during the period $ 127.14 $ 116.64
Restricted stock awards granted during the period 469.31 451.42
-30-
-- 31 of 59 --
12. Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at March 31, 2023 and 2022 is as follows:
March 31
2023 2022
(Restated)
Net unrealized investment (losses) gains:
Beginning of period balance $ (1,755) $ 494
Other comprehensive gain (loss) before reclassifications, net of tax (expense) benefit of $(85)
and $355, respectively 337 (1,146)
Amounts reclassified from accumulated other comprehensive loss, net of tax benefit (expense)
of $(29) and $(21), respectively 90 77
Other comprehensive income (loss) 427 (1,069)
Other comprehensive (income) loss attributable to noncontrolling interests, net of tax benefit of
$0 and $(2), respectively (2) 5
End of period balance (1,330) (570)
Non-credit components of impairments on investments:
Beginning of period balance (3) —
Other comprehensive loss, net of tax benefit of $1 and $1, respectively (2) (1)
End of period balance (5) (1)
Net cash flow hedges:
Beginning of period balance (229) (239)
Other comprehensive income, net of tax benefit (expense) of $8 and $(1), respectively 11 3
End of period balance (218) (236)
Pension and other postretirement benefits:
Beginning of period balance (499) (429)
Other comprehensive income, net of tax expense of $(1) and $(2), respectively 2 7
End of period balance (497) (422)
Future policy benefits:
Beginning of period balance 13 (19)
Other comprehensive income, net of tax expense of $0 and $3, respectively 2 9
End of period balance 15 (10)
Foreign currency translation adjustments:
Beginning of period balance (17) (4)
Other comprehensive income (loss), net of tax benefit of $0 and $1, respectively 2 (3)
End of period balance (15) (7)
Total:
Total beginning of period accumulated other comprehensive loss (2,490) (197)
Total other comprehensive income (loss), net of tax (expense) benefit of $(106) and $336,
respectively 442 (1,054)
Total other comprehensive (income) loss attributable to noncontrolling interests, net of tax benefit
of $0 and $(2), respectively (2) 5
Total end of period accumulated other comprehensive loss $ (2,050) $ (1,246)
-31-
-- 32 of 59 --
13. Earnings per Share
The denominator for basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 is as
follows:
Three Months Ended
March 31
2023 2022
Denominator for basic earnings per share – weighted-average shares 237.5 241.4
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and
convertible debentures 2.2 3.0
Denominator for diluted earnings per share 239.7 244.4
During the three months ended March 31, 2023 and 2022, weighted-average shares related to certain stock options of 0.4
and 0.2, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options
were anti-dilutive.
During the three months ended March 31, 2023, we issued approximately 0.6 restricted stock units under our stock
incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period
of 2023 through 2025. During the three months ended March 31, 2022, we issued approximately 0.5 restricted stock units
under our stock incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the
three-year period of 2022 through 2024. The contingent restricted stock units have been excluded from the denominators for
diluted earnings per share and will be included only if and when the contingency is met.
14. Segment Information
As discussed in Note 1 “Organization”, we are reorganizing our brand portfolio into three core go-to-market brands over
the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance
company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we manage our business
and the products in each of our operating segments, which has resulted in restructurings between some of our operating
segments. As a result of these changes, we have changed our reportable segment presentation and its composition to reflect
how we began managing our operations and monitoring performance, aligning strategies and allocating resources beginning
on January 1, 2023. The results of our operations are now reported in the following four reportable segments: Health Benefits
(aggregates our previously reported Commercial & Specialty Business and Government Business segments), CarelonRx,
Carelon Services (previously included in our Other segment) and Corporate & Other. In 2022, we managed and presented our
operations through the following four reportable segments: Commercial & Specialty Business, Government Business,
CarelonRx and Other. Previously reported information throughout this Form 10-Q has been reclassified to conform to the
new presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer
Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health
Benefits segment also includes our National Government Services. The Health Benefits segment offers health products on a
full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a
variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and
supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services to our
affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a
comprehensive pharmacy services portfolio, which includes services such as formulary management, pharmacy networks,
specialty and home delivery pharmacy services and member services.
Our Carelon Services segment is focused on lowering the cost and improving the quality of healthcare by enabling and
creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic
conditions. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external
customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity
services and subrogation services, as well as health and wellness programs.
-32-
-- 33 of 59 --
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an
operating segment, as well as corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and service fees. Operating revenues are
derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy
products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and
operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon
Services, in addition to certain back-office services provided by our international businesses, which are recorded at cost or
management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three months ended March 31, 2023 and 2022 is as follows:
Carelon
Health
Benefits CarelonRx Carelon
Services Total Corporate
& Other Eliminations Total
Three Months Ended March
31, 2023
Premiums $ 35,534 $ — $ 410 $ 410 $ — $ (76) $ 35,868
Product revenue — 4,022 — 4,022 — — 4,022
Service fees 1,746 — 207 207 55 — 2,008
Operating revenue -
unaffiliated 37,280 4,022 617 4,639 55 (76) 41,898
Operating revenue - affiliated — 4,002 2,695 6,697 196 (6,893) —
Operating revenue - total $ 37,280 $ 8,024 $ 3,312 $ 11,336 $ 251 $ (6,969) $ 41,898
Operating gain (loss) $ 2,159 $ 512 $ 209 $ 721 $ (49) $ — $ 2,831
Three Months Ended March
31, 2022
Premiums $ 32,463 $ — $ 366 $ 366 $ — $ (44) $ 32,785
Product revenue — 3,301 — 3,301 — — 3,301
Service fees 1,564 — 226 226 10 — 1,800
Operating revenue -
unaffiliated 34,027 3,301 592 3,893 10 (44) 37,886
Operating revenue - affiliated — 3,382 2,356 5,738 263 (6,001) —
Operating revenue - total $ 34,027 $ 6,683 $ 2,948 $ 9,631 $ 273 $ (6,045) $ 37,886
Operating gain (loss) (restated) $ 1,851 $ 398 $ 200 $ 598 $ (22) $ — $ 2,427
For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include
adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated
eliminations.
-33-
-- 34 of 59 --
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated
statements of income for the three months ended March 31, 2023 and 2022 is as follows:
Three Months Ended
March 31
2023 2022
Reportable segments’ operating revenue $ 41,898 $ 37,886
Net investment income 387 360
Net losses on financial instruments (113) (151)
Total revenues $ 42,172 $ 38,095
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our
consolidated statements of income for the three months ended March 31, 2023 and 2022 is as follows:
Three Months Ended
March 31
2023 2022
(Restated)
Income before income tax expense $ 2,619 $ 2,306
Net investment income (387) (360)
Net losses on financial instruments 113 151
Interest expense 251 201
Amortization of other intangible assets 235 129
Reportable segments’ operating gain $ 2,831 $ 2,427
15. Leases
We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases
have remaining lease terms of 1 year to 11 years.
The information related to our leases is as follows:
Balance Sheet Location March 31, 2023 December 31, 2022
Operating Leases
Right-of-use assets Other noncurrent assets $ 597 $ 604
Lease liabilities, current Other current liabilities 178 181
Lease liabilities, noncurrent Other noncurrent liabilities 727 751
-34-
-- 35 of 59 --
Three Months Ended
March 31
2023 2022
Lease Expense
Operating lease expense $ 25 $ 28
Short-term and variable lease expense 13 12
Sublease income (1) (1)
Total lease expense $ 37 $ 39
Other information
Operating cash paid for amounts included in the measurement of lease
liabilities, operating leases $ 52 $ 53
Right-of-use assets obtained in exchange for new lease liabilities, operating
leases $ 4 $ —
As of March 31, 2023 and December 31, 2022, the weighted average remaining lease term of our operating leases was 7
years for each period. The lease liabilities reflect a weighted average discount rate of 3.19% at March 31, 2023 and 2.98% at
December 31, 2022.
Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as
follows:
2023 (excluding the three months ended March 31, 2023) $ 162
2024 185
2025 152
2026 118
2027 85
Thereafter 324
Total future minimum payments 1,026
Less imputed interest (121)
Total lease liabilities $ 905
-35-
-- 36 of 59 --
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be
read in conjunction with the accompanying consolidated financial statements and notes, our consolidated financial statements
and notes as of and for the year ended December 31, 2022 and the MD&A included in our 2022 Annual Report on Form 10-
K. References to the terms “we,” “our,” “us,” or “Elevance Health” used throughout this MD&A refer to Elevance Health,
Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the
“states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the three months ended March 31,
2023 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, 2023,
or any other period.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest
health insurers in the United States in terms of medical membership, serving greater than 48 million medical members
through our affiliated health plans as of March 31, 2023. We are an independent licensee of the Blue Cross and Blue Shield
Association (“BCBSA”), an association of independent health benefit plans, and serve members as the Blue Cross or Blue
Cross and Blue Shield licensee in 14 states. We are licensed to conduct insurance operations in all 50 states, the District of
Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services and other
healthcare-related services.
As we announced in 2022, over the next several years we are organizing our brand portfolio into the following core go-
to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated
Blue Cross and/or Blue Shield licensed plans; and
• Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and commercial plans under the
Wellpoint name; and
• Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and
Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime,
trusted health partner. Given this evolution, we reviewed and modified how we manage our business, monitor our
performance and allocate our resources, and made changes to our reportable segments beginning in the first quarter of 2023.
The results of our operations are now reported in the following four reportable segments: Health Benefits (aggregates our
previously reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services
(previously included in our Other segment) and Corporate & Other (our businesses that do not individually meet the
quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable
segments). In 2022, we managed and presented our operations through the following four reportable segments: Commercial
& Specialty Business, Government Business, CarelonRx and Other. Previously reported information in this Form 10-Q has
been reclassified to conform to the new presentation. For additional information, see Note 14, “Segment Information,” of the
Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2022 Annual Report on Form 10-
K.
-36-
-- 37 of 59 --
Business Trends
In 2022, we made the decision to modestly expand our participation in the Individual state- or federally-facilitated
marketplaces (the “Public Exchange”) for 2023, after also modestly expanding in 2022. As a result, for 2023, we are offering
Individual Public Exchange products in 138 of the 143 rating regions in which we operate, in comparison to 122 of 143 rating
regions in 2022. Our strategy has been, and will continue to be, to only participate in rating regions where we have an
appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors
such as expected financial performance, regulatory environment and underlying market characteristics. Changes to our
business environment are likely to continue as elected officials at the national and state levels continue to enact, and both
elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations,
including changes to taxes and fees. In addition, the continuing growth in our government-sponsored business exposes us to
increased regulatory oversight.
Our CarelonRx subsidiary markets and offers pharmacy services to our affiliated health plan customers throughout the
country, as well as to customers outside of the health plans we own. Our comprehensive pharmacy services portfolio includes
features such as formulary management, pharmacy networks, specialty and home delivery pharmacy services and member
services. CarelonRx delegates certain pharmacy services, such as claims processing and prescription fulfillment, to
CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement, which is
set to terminate on December 31, 2024. With CarelonRx, we retain the responsibilities for clinical and formulary strategy and
development, member and employer experiences, operations, sales, marketing, account management and retail network
strategy.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends.
We continue to closely monitor the COVID-19 pandemic (including new COVID-19 variants, which may be more contagious
or severe, or less responsive to treatment or vaccines) and the impacts it may have on our pricing. We frequently make
adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing
competitors and new market entrants. Revenues from the Medicare and Medicaid programs are dependent, in whole or in
part, upon annual funding from the federal government and/or applicable state governments. Product pricing remains
competitive.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all
provider types and the unit cost increases of these services. We work to mitigate these trends through various medical
management programs such as care and condition management, program integrity and specialty pharmacy management and
utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause
variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the
population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical
technology, new high-cost prescription drugs, provider contracting inflation, labor costs and healthcare provider or member
fraud.
Drivers of medical cost trend in the first quarter of 2023 include decreases in COVID-19 healthcare related expenses
compared to prior year experience. The Omicron variant increased COVID-19 healthcare related expenses in the beginning of
2022, then quickly declined during the first quarter of 2022. COVID-19 claim costs for the first quarter of 2023 were lower
than the prior year. The ongoing cost and volume of covered services related to the COVID-19 pandemic and a future shift of
government supplied vaccinations and treatments to privatized, full cost price points may have an adverse effect on our future
claim costs. We continue to closely monitor the COVID-19 pandemic and its impacts on our medical cost trends.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2022 Annual Report
on Form 10-K.
-37-
-- 38 of 59 --
Regulatory Trends and Uncertainties
With the declaration of COVID-19 as a public health emergency (“PHE”) in January 2020, the federal and state
governments enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that
have had, and we expect will continue to have, a significant impact on health benefits, consumer eligibility for public
programs and our cash flows for all of our lines of business and which have introduced increased uncertainty around our cost
structure. These actions, which are or have been in effect for various durations, provide, among other things: mandates to
waive cost-sharing for COVID-19 testing, vaccines and related services; financial support to healthcare providers; and
mandates related to prior authorizations, payment levels to providers, consumer enrollment windows and telehealth services.
The Biden administration renewed the PHE on January 11, 2023 and has indicated that they intend for the PHE to expire on
May 11, 2023.
Under the Consolidated Appropriations Act of 2023 (the “2023 Appropriations Act”), Congress decoupled Medicaid
eligibility recertification from the PHE. As a result, states were permitted to begin removing ineligible beneficiaries from
their Medicaid programs starting April 1, 2023. As recertifications resume, we expect a decline in our Medicaid membership.
At the same time, we expect growth in our commercial risk-based and fee-based plans and Medicare, including through the
Public Exchanges, as members exiting Medicaid in our 14 commercial states seek coverage elsewhere.
The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that
impact our business including an extension of the American Rescue Plan Act of 2021’s enhanced Premium Tax Credits
(“PTC”) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on
repurchases of stock made after December 31, 2022; allowing CMS to negotiate prices on a limited set of prescription drugs
in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning
of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation;
and delaying the implementation of the Trump Administration Medicare drug rebate rule until 2032. The extension of the
enhanced PTC will likely allow for growth in Individual exchange market enrollment, as Medicaid eligibility recertifications
resume, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021 (the “Appropriations Act”) has impacted and in the future may have a
material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new
mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health
parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the Appropriations Act applicable
to us have varying effective dates, some of which were effective in December 2021 and others that have been extended into
2023 since the enactment of the Appropriations Act.
The health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human
Services, Labor and Treasury required us to begin disclosing in July 2022, on a monthly basis, detailed pricing information
regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and
historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we are now
required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for
500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items
and services.
Since its enactment in 2010, the Patient Protection and Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010, as amended (collectively, the “ACA”), has introduced new risks, regulatory challenges and
uncertainties, has impacted our business model and strategy and has required changes in the way our products are designed,
underwritten, priced, distributed and administered. We expect the ACA will continue to significantly impact our business and
results of operations, including pricing, minimum medical loss ratios and the geographies in which our products are available.
We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving
methodology for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data
submitted under the risk adjustment programs in ways that could increase financial recoveries from plans. We will continue
to evaluate the impact of the ACA as any further developments occur.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business –
Regulation”, Part I, Item 1A, “Risk Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7,
-38-
-- 39 of 59 --
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2022 Annual
Report on Form 10-K.
Other Significant Items
Business and Operational Matters
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp
Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and
individuals. Upon closing, we and The Standard will enter into a product distribution partnership. The divestiture is expected
to close by the end of the first quarter of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity
Company, d/b/a Blue Cross and Blue Shield of Louisiana (“BCBSLA”), an independent licensee of the BCBSA that provides
healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana.
This acquisition aligns with our mission to become a lifetime, trusted health partner as we bring our innovative whole-health
solutions to BCBSLA’s members. The acquisition is expected to close by the end of the fourth quarter of 2023 and is subject
to standard closing conditions and customary approvals.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from
CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy
organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of
specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition
aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs
that improve the lives of the people we serve.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term
care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live
safely and independently in their own homes.
For additional information, see Note 3, “Business Acquisitions and Divestitures,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the
“Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/
or Blue Shield licensees, including us (the “Blue plans”) previously approved a settlement agreement and release with the
plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement Agreement”), which
agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge
elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases
were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber
Settlement Agreement applies only to the subscriber class. The defendants continue to contest the consolidated cases brought
by the provider plaintiffs.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval
Order”). In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in
September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals are
proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event all appellate rights are exhausted in a
manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the
Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with
the Subscriber Settlement Agreement. For additional information regarding the BCBSA Litigation, see Note 10,
“Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of
the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-39-
-- 40 of 59 --
Selected Operating Performance
For the twelve months ended March 31, 2023, total medical membership increased by 1.3 million, or 2.9%. Our
membership increase was primarily driven by growth in our Medicaid business, increased sales to our commercial fee-based
employers and growth in both our Medicare Advantage and Individual Public Exchange products, partially offset by attrition
in our Group risk-based business.
Operating revenue for the three months ended March 31, 2023 was $41,898, an increase of $4,012, or 10.6%, from the
three months ended March 31, 2022. Operating revenue increased primarily as a result of higher premiums due to
membership growth in our Medicaid business, membership growth in our Medicare Advantage business, premium rate
increases in our Health Benefits business to more accurately reflect current cost of care and growth in CarelonRx pharmacy
product revenue driven by growth in integrated medical and standalone pharmacy customers.
Net income for the three months ended March 31, 2023 was $2,004, an increase of $225, or 12.6%, from the three
months ended March 31, 2022. The increase in net income was primarily due to operating gain increases in our business
segments, increases in net investment income and lower net losses on financial instruments. These increases were partially
offset by increased amortization of other intangible assets, higher income taxes and increased interest expense.
Our fully-diluted shareholders’ earnings per share (“EPS”) was $8.30 for the three months ended March 31, 2023, which
represented a 13.4% increase from EPS of $7.32 for the three months ended March 31, 2022. The increase in EPS for the
three months ended March 31, 2023 resulted primarily from increased net income.
Operating cash flow for the three months ended March 31, 2023 and 2022 was $6,469 and $2,541, respectively. The
increase was primarily due to early receipt of April 2023’s premium payments from CMS, timing of working capital changes
and higher net income for the three months ended March 31, 2023.
-40-
-- 41 of 59 --
Membership and Other Metrics
The following table presents our medical membership by customer type as of March 31, 2023 and 2022. Also included
below are other membership by product and other metrics. The membership data and other metrics presented are unaudited
and in certain instances include estimates of the number of members represented by each contract at the end of the
period. CarelonRx Quarterly Adjusted Scripts metric represents adjusted script volume based on the number of days a
prescription covers. On an adjusted basis, one 90-day script counts the same as three 30-day scripts. The Carelon Services
Consumers Served metric represents the number of consumers receiving one or more healthcare-related services from
Carelon Services who are members of our affiliated health plans as well as those who are members of non-affiliated health
plans. For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2022 Annual
Report on Form 10-K.
March 31
2023 2022 Change % Change
Medical Membership (in thousands)
Individual 942 818 124 15.2 %
Employer Group Risk-Based 3,798 4,028 (230) (5.7) %
Commercial Risk-Based 4,740 4,846 (106) (2.2) %
BlueCard® 6,607 6,370 237 3.7 %
Employer Group Fee-Based 20,278 20,148 130 0.6 %
Commercial Fee-Based 26,885 26,518 367 1.4 %
Medicare Advantage 2,053 1,921 132 6.9 %
Medicare Supplement 925 939 (14) (1.5) %
Total Medicare 2,978 2,860 118 4.1 %
Medicaid 11,889 10,919 970 8.9 %
Federal Employees Health Benefits (“FEHB”) 1,632 1,632 — — %
Total Medical Membership 48,124 46,775 1,349 2.9 %
Other Membership (in thousands)
Life and Disability Members 4,771 4,679 92 2.0 %
Dental Members 6,743 6,649 94 1.4 %
Dental Administration Members 1,697 1,588 109 6.9 %
Vision Members 9,904 9,211 693 7.5 %
Medicare Part D Standalone Members 264 279 (15) (5.4) %
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts 75.7 73.0 2.7 3.7 %
Carelon Services Consumers Served 104.0 104.0 — — %
Medical Membership
Medical membership increased primarily due to growth in our Medicaid business, increased sales to our commercial fee-
based employers and growth in both our Medicare Advantage and Individual Public Exchange products, partially offset by
attrition in our Employer Group risk-based business.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase
our other products that are ancillary to our health business. Life and disability membership increased primarily due to new
sales of disability products. Dental membership increased primarily due to new sales in our Employer Group risk-based
accounts and increases in our FEHB program. Dental administration membership increased primarily due to favorable in-
-41-
-- 42 of 59 --
group change with other BCBSA plans associated with the FEHB program. Vision membership increased due to sales
exceeding lapses in our Employer Group risk-based accounts and increases associated with Medicare Advantage plans.
Other Metrics
CarelonRx quarterly adjusted scripts increased due to growth in our integrated medical and standalone pharmacy
customers.
Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the three months ended March 31,
2023 and 2022 are as follows:
Three Months Ended
March 31
2023 2022 Change % Change
(Restated)
Total operating revenue $ 41,898 $ 37,886 $ 4,012 10.6 %
Net investment income 387 360 27 7.5 %
Net losses on financial instruments (113) (151) 38 (25.2) %
Total revenues 42,172 38,095 4,077 10.7 %
Benefit expense 30,786 28,231 2,555 9.1 %
Cost of products sold 3,481 2,883 598 20.7 %
Operating expense 4,800 4,345 455 10.5 %
Other expense1 486 330 156 47.3 %
Total expenses 39,553 35,789 3,764 10.5 %
Income before income tax expense 2,619 2,306 313 13.6 %
Income tax expense 615 527 88 16.7 %
Net income $ 2,004 $ 1,779 $ 225 12.6 %
Net (income) loss attributable to noncontrolling interests (15) 10 (25) NM
Shareholders’ net income $ 1,989 $ 1,789 $ 200 11.2 %
Average diluted shares outstanding 239.7 244.4 (4.7) (1.9) %
Diluted shareholders’ net income per share $ 8.30 $ 7.32 $ 0.98 13.4 %
Effective tax rate 23.5 % 22.9 % 60 bp3
Benefit expense ratio2 85.8 % 86.1 % (30) bp3
Operating expense ratio4 11.5 % 11.5 % 0 bp3
Income before income tax expense as a percentage of total revenues 6.2 % 6.1 % 10 bp3
Shareholders’ net income as a percentage of total revenues 4.8 % 4.7 % 10 bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM Not meaningful.
1 Includes interest expense and amortization of other intangible assets.
2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended March 31, 2023 and 2022
were $35,868 and $32,785, respectively.
3 bp = basis point; one hundred basis points = 1%.
4 Operating expense ratio represents operating expense as a percentage of total operating revenue.
Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022
Total operating revenue increased primarily as a result of higher premiums due to membership growth in our Medicaid
business, membership growth in our Medicare Advantage business and premium rate adjustments in our Health Benefits
business to more accurately reflect current cost of care. The increase in operating revenue was further attributable to growth
in CarelonRx pharmacy product revenue driven by growth in members served and script volume.
-42-
-- 43 of 59 --
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by
reduced investment income from alternative investments.
Net losses on financial instruments decreased primarily due to lower mark-to-market losses on equity securities still held
at the period end date and reduced net losses on the sale of fixed maturity securities, partially offset by lower net gains on
other invested assets.
Benefit expense increased primarily due to healthcare costs associated with membership growth in our Medicaid and
Medicare businesses.
Our benefit expense ratio decreased, driven by our commercial risk-based health plans, inclusive of the realignment of
certain quality improvement costs from benefit expense to operating expense following regulatory clarification in 2022.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated customers. Cost of
products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to increased costs to support membership growth.
Our operating expense ratio remained unchanged from the first quarter of 2022. Our operating expense ratio increased
due to the realignment of certain quality improvement expenses discussed above. This increase was offset by a decline in our
operating expense ratio driven by expense leverage associated with strong growth in our operating revenue.
Other expense increased primarily due to additional amortization of other intangible assets as well as increased interest
expense.
Our effective income tax rate increased in 2023 primarily due to the tax impact of expected geographic changes in our
mix of 2023 earnings and reduced investment tax credits.
Our shareholders’ net income as a percentage of total revenues increased in 2023 as compared to 2022 as a result of all
factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted
accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in
understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as
premium income, product revenue and service fees. Operating gain is calculated as total operating revenue less benefit
expense, cost of products sold and operating expense. It does not include net investment income, net (losses) gains on
financial instruments, interest expense, amortization of other intangible assets or income taxes, as these items are managed in
our corporate shared service environment and are not the responsibility of operating segment management. Operating margin
is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment
performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This
information is not intended to be considered in isolation or as a substitute for income before income tax expense,
shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures
reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue
included in the consolidated statements of income and a reconciliation of income before income tax expense to reportable
segments’ operating gain, see Note 14, “Segment Information,” of the Notes to Consolidated Financial Statements included
in Part I, Item 1 of this Form 10-Q.
As discussed in Note 1 “Organization”, of the Notes to Consolidated Financial Statements included in Part I, Item 1 of
this Form 10-Q, we are reorganizing our brand portfolio into three core go-to-market brands over the next several years. Our
branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted
health partner, and our reportable segment presentation and its composition as of January 1, 2023 reflects changes associated
with this evolution and new branding strategy. The results of our operations are now reported in the following four reportable
segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business and Government Business
segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses
-43-
-- 44 of 59 --
that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated
to our other reportable segments). In 2022, we managed and presented our operations through the following four reportable
segments: Commercial & Specialty Business, Government Business, CarelonRx and Other. Previously reported information
in this Form 10-Q has been reclassified to conform to the new presentation. For additional information, see Note 14,
“Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
The following table presents a summary of the reportable segment financial information for the three months ended
March 31, 2023 and 2022:
Three Months Ended
March 31
2023 2022 Change % Change
Operating Revenue
Health Benefits $ 37,280 $ 34,027 $ 3,253 9.6 %
CarelonRx 8,024 6,683 1,341 20.1 %
Carelon Services 3,312 2,948 364 12.3 %
Corporate & Other 251 273 (22) (8.1) %
Eliminations (6,969) (6,045) (924) 15.3 %
Total operating revenue $ 41,898 $ 37,886 $ 4,012 10.6 %
Operating Gain (Loss) (Restated)
Health Benefits $ 2,159 $ 1,851 $ 308 16.6 %
CarelonRx 512 398 114 28.6 %
Carelon Services 209 200 9 4.5 %
Corporate & Other (49) (22) (27) NM
Operating Margin
Health Benefits 5.8 % 5.4 % 40 bp
CarelonRx 6.4 % 6.0 % 40 bp
Carelon Services 6.3 % 6.8 % (50) bp
NM Not meaningful.
bp = basis point; one hundred basis points = 1%.
Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022
Health Benefits
Operating revenue increased primarily due to higher premiums from membership growth in our Medicaid business,
membership growth in our Medicare Advantage business and premium rate increases to more accurately reflect our post-
pandemic cost structure.
Operating gain increased primarily due to premium rate adjustments to more accurately reflect our post-pandemic cost
structure and membership growth in our Medicaid business.
CarelonRx
Operating revenue and operating gain increased primarily as a result of growth in CarelonRx pharmacy product revenue
driven by growth in integrated medical and standalone pharmacy customers.
Carelon Services
Operating revenue increased primarily due to higher revenue for post-acute care services performed for our Medicare
business and behavioral health services performed for our Medicaid business.
The increase in operating gain was primarily driven by improved performance in our care delivery risk business and the
expansion of our post-acute care services, partially offset by higher medical cost trends in our behavioral health business.
-44-
-- 45 of 59 --
Corporate & Other
Operating revenue decreased primarily due to lower affiliated revenues in our international operations.
Operating loss increased primarily due to an increase in unallocated corporate expenses.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management
to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and
accompanying notes and within this MD&A. We consider our most important accounting policies that require significant
estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes,
goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are
discussed in our 2022 Annual Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,”
to our audited consolidated financial statements as of and for the year ended December 31, 2022, as well as in the “Critical
Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations.” As of March 31, 2023, our critical accounting policies and estimates have not changed
from those described in our 2022 Annual Report on Form 10-K.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims
payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of
March 31, 2023, our critical accounting policies and estimates related to medical claims payable have not changed from those
described in our 2022 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical
claims payable for the three months ended March 31, 2023 and 2022, see Note 8, “Medical Claims Payable,” of the Notes to
Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred
but not paid liability estimates for the three months ended March 31, 2023 and 2022, which are the trend and completion
factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs,
provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing
patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by
Changes in Key Assumptions
Three Months Ended
March 31
2023 2022
Assumed trend factors $ 772 $ 880
Assumed completion factors 296 53
Total $ 1,068 $ 933
The favorable development recognized in the three months ended March 31, 2023 and 2022 resulted primarily from
trend factors in late 2022 and late 2021, respectively, developing more favorably than originally expected. Favorable
development in the completion factors resulting from the latter part of 2022 developing faster than expected also contributed
to the favorable development for the three months ended March 31, 2023.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 64.9% and
61.0% for the three months ended March 31, 2023 and 2022, respectively. This ratio serves as an indicator of claims
processing speed whereby speed for claims payments was slightly higher during the three months ended March 31, 2023 as
compared to the three months ended March 31, 2022.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims
payable less prior year redundancies in the current period in order to demonstrate the development of prior year reserves. For
the three months ended March 31, 2023, this metric was 7.5%, largely driven by favorable trend factor development at the
-45-
-- 46 of 59 --
end of 2022 as well as favorable completion factor development factor from 2021. For the three months ended March 31,
2022, this metric was 7.6%, largely driven by favorable trend factor development at the end of 2021.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred
medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net
incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred
medical claims and the consistency in our methodology. For the three months ended March 31, 2023, this metric was 0.9%,
which was calculated using the redundancy of $1,068. For the three months ended March 31, 2022, the comparable metric
was 0.9%, which was calculated using the redundancy of $933. We believe these metrics demonstrate an appropriate level of
reserve conservatism.
New Accounting Pronouncements
We adopted accounting standard amendments on long-duration insurance accounting which became effective for us on
January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and
deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material
impact, our prior period financial statements presented in this Form 10-Q have been restated to reflect the impacts of our
adoption as required by the new standard. For more information regarding this new accounting pronouncement that was
adopted, see the “Recently Adopted Accounting Guidance” sections of Note 2, “Basis of Presentation and Significant
Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the
sale or maturity of our investment securities, proceeds from borrowings and proceeds from the issuance of common stock
under our employee stock plans. Cash disbursements result mainly from claims payments, operating expenses, taxes,
purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases
of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and
timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on
our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included
in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” included in our 2022 Annual Report on Form 10-K.
For additional information regarding our sources and uses of capital during the three months ended March 31, 2023, see
Note 5, “Derivative Financial Instruments,” Note 9, “Debt,” and Note 11, “Capital Stock – Use of Capital – Dividends and
Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-46-
-- 47 of 59 --
Liquidity
A summary of our major sources and uses of cash and cash equivalents for the three months ended March 31, 2023 and
2022 is as follows:
Three Months Ended
March 31
2023 2022 Change
Sources of Cash:
Net cash provided by operating activities $ 6,469 $ 2,541 $ 3,928
Issuances of commercial paper and short- and long-term debt, net of repayments 991 211 780
Proceeds from issuance of common stock under employee stock plans 43 76 (33)
Other sources of cash, net — 420 (420)
Total sources of cash 7,503 3,248 4,255
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and
redemptions (1,421) (794) (627)
Purchases of subsidiaries, net of cash acquired (1,638) (61) (1,577)
Repurchase and retirement of common stock (622) (545) (77)
Purchases of property and equipment (301) (254) (47)
Cash dividends (351) (309) (42)
Other uses of cash, net (416) — (416)
Total uses of cash (4,749) (1,963) (2,786)
Effect of foreign exchange rates on cash and cash equivalents 1 (4) 5
Net increase in cash and cash equivalents $ 2,755 $ 1,281 $ 1,474
The increase in net cash provided by operating activities was primarily due to the early receipt of April 2023’s premium
payments from CMS, timing of working capital changes and higher net income for the three months ended March 31, 2023.
Other significant changes in sources or uses of cash year-over-year included higher amounts for purchases of
subsidiaries, net of cash acquired and purchase of investments, net of proceeds from sales, maturities, calls and redemptions.
These additional uses of cash were partially offset by increased issuances of commercial paper and short- and long-term debt,
net of repayments.
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and
investments in fixed maturity and equity securities of $38,953 at March 31, 2023. Since December 31, 2022, total cash, cash
equivalents and investments in fixed maturity and equity securities increased by $3,909, primarily due to cash generated from
operations and an increase in market value of our fixed maturity securities. These increases were partially offset by cash used
for the purchase of subsidiaries, cash used for common stock repurchases, dividends paid to shareholders and the purchase of
property and equipment.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends
and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by
insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory
accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain
undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our
subsidiaries.
At March 31, 2023, we held $1,062 of cash, cash equivalents and investments at the parent company, which are available
for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases
and dividends to shareholders, repurchases of debt securities and debt and interest payments.
Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to
refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us
-47-
-- 48 of 59 --
to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the
occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 9, “Debt,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our
consolidated balance sheets included in Part I, Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt
divided by total debt plus total shareholders’ equity. Total debt is the sum of short-term borrowings, current portion of long-
term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating agencies in
measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-
to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled
measures reported by other companies. Our consolidated debt-to-capital ratio was 40.5% and 39.9% as of March 31, 2023
and December 31, 2022, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor
Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our
credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely
impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited
amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and
securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for
general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our
subsidiaries, the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes.
The 5-Year Facility provides for a credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year
Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-
capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year
Facility. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or
operating flexibility. We had no amounts outstanding as of March 31, 2023 or December 31, 2022. As of March 31, 2023, we
were in compliance with all of the debt covenants under the 5-Year Facility.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”)
with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit up to $200.
Our ability to borrow under the Subsidiary Credit Facilities is subject to compliance with certain covenants. At March 31,
2023 and December 31, 2022, we had no outstanding borrowings under the Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general
corporate purposes. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash
on hand and/or our 5-Year Facility to redeem any outstanding commercial paper upon maturity. At March 31, 2023 and
December 31, 2022, we had $325 and $0, respectively, outstanding under our commercial paper program.
While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year
Facility and Subsidiary Credit Facilities, if market conditions allow, would be willing to provide financing in accordance with
their legal obligations.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan
Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the
“FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral
requirements. We had $265 of outstanding short-term borrowings from the FHLBs at each of March 31, 2023 and
December 31, 2022.
-48-
-- 49 of 59 --
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases
and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is
at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity
needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at March 31, 2023, see Note 4, “Investments,” Note
5, “Derivative Financial Instruments,” Note 9, “Debt,” and Note 11, “Capital Stock – Use of Capital – Dividends and Stock
Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile
have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance
organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC)
for Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to measure capital
adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the
formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest
rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC
Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance
commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of
December 31, 2022, which was the most recent date for which reporting was required, were in excess of all applicable
mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and
capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our
California subsidiaries. For additional information, see Note 22, “Statutory Information,” in our audited consolidated
financial statements as of and for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.
Future Sources and Uses of Liquidity
We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial
paper program, our 5-Year Facility and our Subsidiary Credit Facilities and borrowings available from the FHLBs will be
adequate to fund our expected cash disbursements over the next twelve months.
There have been no material changes to our long-term liquidity requirements as disclosed in our 2022 Annual Report on
Form 10-K. For additional updates regarding our estimated long-term liquidity requirements, see Note 5, “Derivative
Financial Instruments,” Note 9, “Debt,” and the “Other Contingencies” and “Contractual Obligations and Commitments”
sections of Note 10 “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part I,
Item 1 of this Form 10-Q. We believe that funds from future operating cash flows, cash and investments and funds available
under our 5-Year Facility and/or from public or private financing sources will be sufficient for future operations and
commitments, and for capital acquisitions and other strategic transactions.
-49-
-- 50 of 59 --
FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are
generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,”
“estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements.
These statements include, but are not limited to: financial projections and estimates and their underlying assumptions;
statements regarding plans, objectives and expectations with respect to future operations, products and services; and
statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed
in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the
various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from
time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by
law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date
hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced
enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies,
such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes
in existing federal, state and international laws or regulations, including healthcare laws and regulations, or their
enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure
to comply with any privacy or security laws or regulations, including any investigations, claims or litigation related thereto;
information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively
affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and
develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs,
including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve
improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with
respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other
liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on
cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated
with providing pharmacy, healthcare and other diversified products and services, including medical malpractice or
professional liability claims and non-compliance by any party with the pharmacy services agreement between us and
CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible
assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of
capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy
of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of
outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further
increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to
the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross
and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international
operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and
business combinations.
-50-
-- 51 of 59 --
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,”
included in our 2022 Annual Report on Form 10-K. There have been no material changes to any of these risks since
December 31, 2022.
ITEM 4. CONTROLS AND PROCEDURES
We carried out an evaluation as of March 31, 2023, under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our
disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our
consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that
evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the
Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief
Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the three months ended
March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For information regarding legal proceedings at March 31, 2023, see the “Litigation and Regulatory Proceedings,” and
“Other Contingencies” sections of Note 10, “Commitments and Contingencies” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q, which information is incorporated herein by reference.
ITEM 1A. RISK FACTORS
There have been no material changes to the risk factors disclosed in our 2022 Annual Report on Form 10-K.
-51-
-- 52 of 59 --
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)
January 1, 2023 to January 31, 2023 533,655 $ 482.68 533,058 $ 6,619
February 1, 2023 to February 28, 2023 294,308 486.70 293,889 6,476
March 1, 2023 to March 31, 2023 684,708 465.46 477,624 6,254
1,512,671 1,304,571
1 Total number of shares purchased includes 208,100 shares delivered to or withheld by us in connection with employee
payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock
issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these
shares purchased.
2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of
Directors, which the Board of Directors evaluates periodically. During the three months ended March 31, 2023, we
repurchased 1,304,571 shares at a total cost of $622 under the program, including the cost of options to purchase shares.
The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized
increase to the program was $5,000 on January 24, 2023 by our Audit Committee, pursuant to authorization granted by
the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right
to discontinue the program at any time.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
None.
ITEM 5. OTHER INFORMATION
None.
-52-
-- 53 of 59 --
ITEM 6. EXHIBITS
Exhibit
Number Exhibit
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June 27,
2022, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28,
2022.
3.2 Bylaws of the Company, as amended effective June 28, 2022, incorporated by reference to Exhibit 3.2 to the
Company’s Current Report on Form 8-K filed on June 28, 2022.
4.7 Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any
other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
10.2 * (o) Form of Incentive Compensation Plan Non Qualified Stock Option Award Agreement for 2023.
* (p) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2023.
* (q) Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2023.
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act
Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act
Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
101 The following material from Elevance Health, Inc.’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2023, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the
Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of
Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of
Changes in Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear
in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
* Indicates management contracts or compensatory plans or arrangements.
-53-
-- 54 of 59 --
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
ELEVANCE HEALTH, INC.
Registrant
April 19, 2023 By: /S/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
April 19, 2023 By: /S/ RONALD W. PENCZEK
Ronald W. Penczek
Chief Accounting Officer and Controller
(Principal Accounting Officer)
-54-
-- 55 of 59 --
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1. I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of
directors (or persons performing the equivalent function):
a) all significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant’s internal control over financial reporting.
April 19, 2023 /s/ GAIL K. BOUDREAUX
President and Chief Executive Officer
Exhibit 31.1
-- 56 of 59 --
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1. I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal
control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of
directors (or persons performing the equivalent function):
a) all significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to
record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant’s internal control over financial reporting.
April 19, 2023 /s/ JOHN E. GALLINA
Executive Vice President and
Chief Financial Officer
Exhibit 31.2
-- 57 of 59 --
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended
March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux,
President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of
the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
April 19, 2023
Exhibit 32.1
-- 58 of 59 --
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended
March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John E. Gallina,
Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
April 19, 2023
Exhibit 32.2
-- 59 of 59 --